Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of tumors, with aggressive clinical course that renders prognostication and choice of treatment strategy difficult. Chemo-immunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) is the cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchesi, Francesco, Regazzo, Giulia, Palombi, Francesca, Terrenato, Irene, Sacconi, Andrea, Spagnuolo, Manuela, Donzelli, Sara, Marino, Mirella, Ercolani, Cristiana, Di Benedetto, Anna, Blandino, Giovanni, Ciliberto, Gennaro, Mengarelli, Andrea, Rizzo, Maria Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930939/
https://www.ncbi.nlm.nih.gov/pubmed/29716630
http://dx.doi.org/10.1186/s13046-018-0768-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930939/
https://www.ncbi.nlm.nih.gov/pubmed/29716630
http://dx.doi.org/10.1186/s13046-018-0768-5

Ejemplares similares